If amplification was identified, consider “type”:”entrez-nucleotide”,”attrs”:”text”:”F15153″,”term_id”:”976042″,”term_text”:”F15153″F15153 (INC280) trial, Phase IB “type”:”clinical-trial”,”attrs”:”text”:”NCT01999972″,”term_id”:”NCT01999972″NCT01999972, or crizotinib and if not present consider ATR or PARP inhibitor trial. were made for 19/21 (90.5%) patients, and